<DOC>
	<DOCNO>NCT01801436</DOCNO>
	<brief_summary>The purpose post marketing study determine plasma concentration bortezomib ( unchanged drug ) ass pharmacokinetic ( PK - study way drug enters leave blood tissue time ) property Taiwanese population . It also provide expanded access ( expanded access , sometimes call `` compassionate use , '' use investigational drug outside clinical trial treat participant serious immediately life-threatening disease condition comparable satisfactory alternative treatment option ) bortezomib group participant multiple myeloma ( cancer type cell normally find bone marrow ) .</brief_summary>
	<brief_title>A Post-Approval Pharmacokinetic Study Bortezomib Participants With Multiple Myeloma</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-arm , multi-center ( conducted 1 center ) study assess PK bortezomib provide expand access bortezomib 14 Taiwanese participant multiple myeloma receive least 2 previous line therapy ( medicine medical care give participant disease condition ) refractory ( respond treatment ) relapse ( return medical problem ) last therapy . Eligible participant receive bortezomib 1.3 milligram ( mg ) per meter square ( m^2 ) Days 1 , 4 , 8 , 11 3-week cycle 8 cycle . Blood sample PK assessment collect specified time point Day 1 , Day 8 , Day 11 Cycle 1 . Efficacy participant primarily evaluate record 'response treatment ' 'Karnofsky Performance Status ' . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Participants previously diagnose multiple myeloma base standard criterion Participant receive least 2 previous line therapy multiple myeloma , Investigator 's opinion , currently require therapy relapse ( return medical problem ) progressive disease Female participants either postmenopausal surgically sterilize willing use acceptable method birth control Screening Final Visit If male , participant agrees use acceptable barrier method contraception Screening Final Visit Participant Karnofsky performance status classify participant functional impairment use compare effectiveness different therapy assess prognosis [ outlook , probable outcome ] individual participant ) great 60 If participant receive bortezomib previous trial , Participants ' best response bortezomib must progressive disease If participant receive bortezomib previous trial , participant must experience 1 serious adverse event Participants receive nitrosoureas within 6 week chemotherapy ( treatment disease , usually cancer , chemical agent ) within 3 week enrollment Participants receive corticosteroid ( great 10 milligram per day prednisone equivalent ) within 3 week enrollment Human Immunodeficiency Virus ( HIV lifethreatening infection get infect person 's blood sex infect person ) positive hepatitisB surface antigenpositive participant participant know active hepatitisC infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
</DOC>